View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Comment
September 21, 2021

Number of resumed trials very gradually increases

As of 17 September, the number of resumed clinical trials tracked by GlobalData's Pharma Intelligence Centre stands at 1,095.

By GlobalData Healthcare

Since early last March, more than 500 companies have publicly announced disruptions to their planned and ongoing clinical trials due to the Covid-19 pandemic. Many companies have delayed the initiation of planned trials or withdrawn them completely, while others have suspended enrollment in their ongoing trials or terminated the trials altogether. The majority of trial disruptions can be attributed to patient safety measures, strict lockdown requirements, social distancing procedures and the high demand on medical professionals to treat Covid-19 patients.

As the initial peak of the virus started declining, many trials were set to resume activity, but the number of confirmed Covid-19 cases is now increasing again due to the emergence of new variants.

The Covid-19 Dashboard on GlobalData’s Pharma Intelligence Centre dynamically tracks both disrupted and resumed trials.

As of 17 September, the number of resumed trials stands at 1,095. Out of these trials, 51.6% are currently recruiting participants, while 22.6% have completed recruitment but are still ongoing, but are yet to start recruiting subjects. The figure below shows that the number of trials resuming has increased slightly, even though the trend is very gradual. This slow increase is mainly due to the rise of global Covid-19 cases, especially the Delta variant. Sponsors are continuing to focus on moving to decentralised or virtual trials to overcome lockdown measures.

The US has the highest proportion of resumed trials at 69.1%, followed by the UK at 9.4%, Spain at 7.5%, France at 7.3% and Germany at 6.7%.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Clinical Trials Arena